Intravesical bacillus Calmette-Guèrin therapy: Experience with a reduced dwell-time in patients with pronounced side-effects

BJU International

Volumn 96, Issue 9, 2005, Pages 1290-1293

  Andius, Patrik ^a   Fehrling, Marianne ^a   Holmäng, Sten ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bacille Calmette Gu rin; Bladder neoplasm; Carcinoma in situ; Optimum dose

Indexed keywords

BCG VACCINE;

ARTICLE; BLADDER CANCER; CARCINOMA IN SITU; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DYSURIA; FEVER; FOLLOW UP; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; PAPILLOMA; PRIORITY JOURNAL; REDUCTION; SIDE EFFECT; URINARY FREQUENCY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; AGED; BCG VACCINE; CARCINOMA IN SITU; CHILLS; FEVER; FOLLOW-UP STUDIES; HEMATURIA; HUMANS; URINARY BLADDER NEOPLASMS; URINATION DISORDERS;

EID: 28544452354     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05817.x     Document Type: Article

References (16)

1. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 115: 180-3
2. Hudson MA, Catalona WJ, Ritchey JK, Aslanzadeh J, Brown EJ, Ratliff TL. Choice of an optimal diluent for intravesical bacillus Calmette-Guerin administration. J Urol 1989; 142: 1438-41
3. Pagano F, Bassi P, Milani C, Meneghini A, Maruzzi D, Garbeglio A. A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? J Urol 1991; 146: 32-5
4. Morales A, Nickel JC, Wilson JWL. Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J Urol 1992; 147: 1256-8
5. Bassi P, Spinardi R, Carando R, Balta G, Pagano F. Modified induction course: a solution to side effects? Eur Urol 2000; 37 (Suppl. 1): 31-2
6. Martinez-Pineiro JA, Flores N, Isorna S et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 2002; 89: 671-80
7. O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 2002; 166: 1300-5
8. Berry DL, Blumenstein BA, Magyary DL, Lamm DL, Crawford ED. Local toxicity patterns associated with intravesical bacillus Calmette-Guerin: a Southwest Oncology Group Study. Int J Urol 1996; 3: 98-101
9. Böhle A, Balck F, von Weitersheim J, Jocham D. The quality of life during intravesical bacillus Calmette-Guerin therapy. J Urol 1996; 155: 1221-6
10. Lockyer CR, Sedgwick JE, Gillatt DA. Beware the BCG failures: a review of one institution's results. Eur Urol 2002; 42: 542-6
11. Griffiths TR, Charlton M, Neal DE, Powell PH. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 2002; 167: 2408-12
12. van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003; 44: 429-34
13. Lamm DL. Superficial bladder cancer. Curr Treat Options Oncol 2002; 3: 403-11
14. Lamm DL, Reichert DF, Harris SC, Lucio RM. Immunotherapy of murine transitional cell carcinoma. J Urol 1982; 128: 1104-8
15. Zlotta AR, van Vooren JP, Huygen K et al. What is the optimal regimen for BCG intravesical therapy? Are six weekly instilllations necessary? Eur Urol 2000; 37: 470-7
16. Saint F, Salomon L, Quintela R et al. Do prognostic parameters of remission versus relapse after bacillus Calmette-Guerin (BCG) immunotherapy exist? Analysis of a quarter century of literature. Eur Urol 2003; 43: 351-61